Completed PHASE2 INTERVENTIONAL 2-arm NCT00721305

Lovastatin: Immunomodulatory Value Evaluation (LIVE)

Antiretroviral Effect of Lovastatin on HIV-1-infected Individuals Without Highly Active Antiretroviral Therapy (HAART): A Phase-II Randomized Clinical Trial (RCT)

Sponsor: Humax Pharmaceutical

Conditions HIV Seropositivity

Interventions Lovastatin placebo

Updated 6 times since 2017 Last updated: Sep 30, 2011 Started: Aug 31, 2008 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates HIV Seropositivity and is currently completed. Humax Pharmaceutical leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Humax Pharmaceutical
Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)
Laboratorio Clínico Congregación Mariana
Laboratorios Laproff S.A.
Universidad de Antioquia

Data source: Universidad de Antioquia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Medellín, Colombia